First-line nivolumab (NIVO) plus ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA

ANNALS OF ONCOLOGY

ELSEVIER

1. Bristol-Myers Squibb Company